Skip to search boxSkip to navigationSkip to main content

Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys

  • Carsten Schröder
    ,
  • Agnes M. Azimzadeh
    ,
  • Guosheng Wu
    ,
  • James O. Price
    ,
  • James B. Atkinson
    ,
  • Richard N. Pierson(corresponding author)
*Corresponding author for this work
  • Vanderbilt University
    ,
  • University of Maryland, Baltimore
    ,
  • VA Medical Center
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

Introduction: Macaque species offer a valuable model for translational allo-transplantation and tolerance studies. Cardiac allograft vasculopathy in Macaca fascicularis is associated with elaboration of anti-donor antibodies. Since T-independent pathways of B cell activation have been described, and anti-B cell strategies have proven to be a fruitful tolerogenic adjunct in rodent and xenogenic models, here we investigate whether an anti-CD20 antibody (rituximab) would be useful to deplete B-cells in a pre-clinical allo-transplantation setting in macaques. Methods: Three cynomolgus macaques which had previously rejected a cardiac allograft and one with concurrent subacute vascular rejection were treated weekly with rituximab 20 mg/kg IV for 4 and 2 weeks, respectively. B-cell levels (CD19+ cells) were measured by flow cytometry in peripheral blood, spleen, lymph node and bone marrow cells at various intervals after initiation of treatment. B-cells and plasma cells were also analyzed by immunohisto-chemistry at necropsy in spleen, lymph node, tonsil and thymus tissue sections. Anti-donor antibody liters were measured by flow cytometry. Results: B-cells expressing CD19 were not detectable in the peripheral blood in any animal within 24 h after initial treatment, or over the ensuing month. At necropsy, the germinal centers in spleen and lymph node were completely depleted of CD20+ B-cells in 2 animals, leaving a hypocellular trabecular pattern around preserved plasma cell follicles. Substantial but incomplete depletion of B-cells was demonstrated in the other 2 animals, in each instance immunohistochemical findings in spleen and lymph node exhibiting higher sensitivity for residual B-cells compared to FACS. Anti-donor antibody tilers exhibited kinetics similar to untreated animals over this short follow-up. Comment: Treatment with anti-CD20 very efficiently depletes peripheral and tissue B-cells but not plasma cells in this macaque species. Biopsy of lymph node is necessary and may be sufficient to assess B-cell clearance in secondary lymphoid organs in this model.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 19-28 (10 pages)

Journal (Volume, Issue Number)

Transplant Immunology (Volume 12, Issue 1)

Publication milestones

  • Published - 10/2003

Publication status

Published - 10/2003

ISSN

0966-3274

Publication IDs

  • Scopus: 10744229262
  • PubMed: 14551029

Publication metrics

Metrics

Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1
SciVal
citations
100
SciVal
FWCI
1.73
SciVal
Author count
6
SciVal
Paper percentile
93
SciVal
Top percentile
10
Scopus
citations

PlumX, opens in new tab

Captures
44
Citation count
108

Funding Details

The authors’ research has been supported by Vanderbilt University, the VUMC General Clinical Research Center, and the Nashville VAMC, and by grants from the American Association of Thoracic Surgeons (RNP), the American Lung Association (RNP, AA), NIH (RNP), VA Merit Review (RNP), and Imutran-Novartis Pharma, (RNP). CS is the recipient of a fellowship from the German Research Foundation (DFG).
FundersFunding numbers
RNP
-
Imutran/A Novartis Pharma AG Company
-
DFG
-
American Lung Association Lung Cancer
-
AATS
-
NIH
-
DFG
-
VU
-